 Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc NASDAQ:NRBO and Windtree Therapeutics Inc NASDAQ:WINT, even though these two securities have shown poor performance over the prior 52 weeks through April 7. They have both reported more than a 59 fall in their share prices. 